SEC-sourced researchBeta
BFRI
Biofrontera Inc.
Company comparison ↗
Data passport
- CIK
- 0001858685
- Exchange
- Nasdaq
- Business activity
- Pharmaceutical Preparations · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Nov 20, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 37,321,000.0000 | Mar 19, 2026 |
| December 2025 | 41,705,000.0000 | Mar 19, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 41,705,000.0000 | -10,536,000.0000 | -13,361,000.0000 | 28,564,000.0000 | 18,084,000.0000 | Mar 19, 2026 |
| December 2024 | 37,321,000.0000 | -17,759,000.0000 | -10,270,000.0000 | 22,101,000.0000 | 17,668,000.0000 | Mar 19, 2026 |
Explainable fundamental score
Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.
40/100
Profitability0
Growth62
Balance sheet37
Cash generation0
Data coverage100
Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $41.71M | Jan 1, 2025 – Dec 31, 2025 | Mar 19, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $37.32M | Jan 1, 2024 – Dec 31, 2024 | Mar 19, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$10.54M | Jan 1, 2025 – Dec 31, 2025 | Mar 19, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$13.36M | Jan 1, 2025 – Dec 31, 2025 | Mar 19, 2026 | 10-K |
| Total assetsAssets | $28.56M | Dec 31, 2025 | Mar 19, 2026 | 10-K |
| Total liabilitiesLiabilities | $18.08M | Dec 31, 2025 | Mar 19, 2026 | 10-K |